Management of Coccidioides Infection

Initial Assessment and Monitoring

The Infectious Diseases Society of America (IDSA) recommends close clinical monitoring with serial serologic testing and chest imaging every 1-3 months for at least one year in patients with rising Coccidioides IgG titers, with antifungal therapy initiated only if symptoms develop, imaging shows progressive disease, or titers rise to ≥1:16 1, 2, 3
Key clinical evaluation points include symptom assessment, chest radiograph, risk factors, and ethnicity consideration, with specific attention to weight loss >10%, night sweats >3 weeks, persistent cough, chest pain, or fatigue 2, 3
The IDSA guidelines emphasize the importance of monitoring for new symptoms, radiographic progression, and development of extrapulmonary manifestations 1, 2, 3

The IDSA recommends initiating oral azole therapy (fluconazole 200-400 mg daily) if CF antibody titer rises to ≥1:16, symptoms become debilitating or persist >2 months, radiographic progression occurs, or extrapulmonary manifestations develop 1, 2, 3
Treatment duration should be 3-6 months for uncomplicated pulmonary disease, with longer courses for severe or disseminated infection 1, 3

Severity indicators warranting treatment include weight loss ≥10%, night sweats >3 weeks duration, infiltrates >50% of one lung or bilateral involvement, prominent/persistent hilar adenopathy, CF titer ≥1:16, and symptoms persisting ≥12 months 1, 2, 4, 5
Extrapulmonary dissemination warning signs include progressive headache or mental status changes, new skin lesions, joint pain/swelling, and bone pain, requiring prompt tissue diagnosis through biopsy/aspiration and lumbar puncture if meningeal signs present 1, 2, 3, 6

Most patients with uncomplicated coccidioidal infection will have antibodies that return to negative as the infection resolves, which differs from many other infections where IgG remains detectable for life 7, 8
Coccidioidal serologic tests may be negative or persistently negative despite an active early infection being present 7, 8

You must evaluate for focal signs and symptoms of disseminated disease, as their absence is strong evidence that dissemination is not present 7

Culture of sputum or bronchoscopic specimens may provide diagnosis when serologic evidence takes weeks to months to develop or never develops 7, 8
Coccidioidal antigen may be positive in extensive infections, though CSF antigen may be sensitive for meningitis 8, 9
Tissue diagnosis through biopsy or aspiration of any suspicious extrapulmonary lesions may be necessary 8

Serologic tests may remain persistently negative despite ongoing infection, so negative serology should not exclude active infection 7, 8